Carboxymethyl chitosan and carboxymethyl cellulose based self-healing hydrogel for accelerating diabetic wound healing.
Carbohydr Polym
; 292: 119687, 2022 Sep 15.
Article
en En
| MEDLINE
| ID: mdl-35725178
ABSTRACT
In this study, a new type of biodegradable, injectable, self-healing, and low-toxic CMCSH, formed by N, O-carboxymethyl chitosan-heparin (CMCS-Hep) and carboxymethyl cellulose-aldehyde (CMC-A), was designed to deliver drug for promoting the progress of the diabetic wound healing. CMCS was modified with Hep for the first time to synthesize CMCS-Hep, and CMC-A was synthesized by the periodate oxidation method. First, SOD encapsulated in the CMCSH was applied to the diabetic wound bed to moderate the microenvironment, then rhEGF retained in the CMCSH was sustainedly released to the wound area. These results indicated that the dual-drug delivery system had the ability to improve drug availability, promote cell migration and proliferation, reduce DNA damage, shorten the inflammatory period, and accelerate the deposition of collagen fibers and the formation of blood vessels in the model with diabetic skin injury, suggesting that CMCSH as drug carriers had positive effects on diabetic wound healing.
Palabras clave
Carboxymethyl cellulose; Carboxymethyl chitosan; Carboxymethyl chitosan (Pubchem CID: 71306969); Control release; Diabetic wound healing; Epidermal growth factor (Pubchem CID: 56841751); Heparin; Self-healing hydrogel; Sodium carboxymethyl cellulose (Pubchem CID: 23706213); Sodium heparin (PubChem CID: 22833565); Sodium periodate (Pubchem CID: 23667635); Streptozocin (Pubchem CID: 29327); Superoxide dismutase (Pubchem CID: 11963501); Tert-butyl carbazate (Pubchem CID: 70091); Toluidine blue O (Pubchem CID: 7083)
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Quitosano
/
Diabetes Mellitus
Tipo de estudio:
Prognostic_studies
Límite:
Humans
Idioma:
En
Revista:
Carbohydr Polym
Año:
2022
Tipo del documento:
Article